AJP - Renal AJP: Cell Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Renal Physiol 287: F25-F32, 2004. First published March 9, 2004; doi:10.1152/ajprenal.00449.2003
0363-6127/04 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
287/1/F25    most recent
00449.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smirnova, I. V.
Right arrow Articles by Goligorsky, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smirnova, I. V.
Right arrow Articles by Goligorsky, M. S.

Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in endothelial cells by nitric oxide deficiency

I. V. Smirnova,1 T. Sawamura,2 and M. S. Goligorsky1

1Department of Medicine, Renal Research Institute, and Division of Nephrology, New York Medical College, Valhalla, New York 10595; and 2Department of Bioscience, National Cardiovascular Center Research Institute, Osaka 565–8565, Japan

Submitted 24 December 2003 ; accepted in final form 5 March 2004

Endothelial cell dysfunction (ECD) is emerging as a common denominator for diverse cardiovascular abnormalities associated with inhibition of endothelial nitric oxide (NO) synthase (eNOS). Elevated levels of asymmetric dimethylarginine (ADMA), a potent eNOS inhibitor, are common in renal failure and may contribute to ECD. Through DNA microarray screening of genes modulated in human umbilical vein endothelial cells (HUVEC) by NG-nitro-L-arginine methyl ester (L-NAME), we found a 1.8-fold increase in low-density lipoprotein receptor-1 (LOX-1) expression. LOX-1 is a major endothelial receptor for oxidized low-density lipoproteins (OxLDL) and is assumed to play a role in the initiation and progression of atherosclerosis. Here, we confirmed the upregulation of LOX-1 mRNA and protein level by quantitative RT-PCR and Western blot analysis. Increased expression of LOX-1 was associated with the accumulation of DiI-labeled OxLDL (DiI-OxLDL) in ADMA- and L-NAME-pretreated HUVEC. To evaluate the contribution of LOX-1 in ADMA-induced accumulation of OxLDL by HUVEC, we used the competitive receptor inhibitor, soluble LOX-1. Treatment of HUVEC with soluble LOX-1 was associated with an approximately two- to threefold inhibition of DiI-OxLDL uptake in L-NAME- or ADMA-treated HUVEC. In conclusion, ADMA- or L-NAME-induced NO deficiency leads to the increased expression of LOX-1 mRNA and protein in HUVEC, which in turn results in the accumulation of OxLDL. Competition with LOX-1-soluble extracellular domain reduces OxLDL accumulation. In summary, elevated ADMA levels, i.e., in patients with renal failure, may be responsible for endothelial accumulation of OxLDL via upregulated LOX-1 receptor, thus contributing to endothelial lipidosis and dysfunction.

asymmetric dimethylarginine; endothelial dysfunction; chronic renal failure



Address for reprint requests and other correspondence: M. S. Goligorsky, Renal Research Institute, Basic Sciences Bldg., Rm. C23, New York Medical College, Valhalla, NY 10595 (E-mail: Michael_Goligorsky{at}nymc.edu).




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
A. Stoessel, A. Paliege, F. Theilig, F. Addabbo, B. Ratliff, J. Waschke, D. Patschan, M. S. Goligorsky, and S. Bachmann
Indolent course of tubulointerstitial disease in a mouse model of subpressor, low-dose nitric oxide synthase inhibition
Am J Physiol Renal Physiol, September 1, 2008; 295(3): F717 - F725.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. S. Goligorsky
Frontiers in Nephrology: Viewing the Kidney through the Heart Endothelial Dysfunction in Chronic Kidney Disease
J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2833 - 2835.
[Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
D. M. Okamura, J. M. Lopez-Guisa, K. Koelsch, S. Collins, and A. A. Eddy
Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury
Am J Physiol Renal Physiol, August 1, 2007; 293(2): F575 - F585.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
E. Monsalve, P. J. Oviedo, M. A. Garcia-Perez, J. J. Tarin, A. Cano, and C. Hermenegildo
Estradiol counteracts oxidized LDL-induced asymmetric dimethylarginine production by cultured human endothelial cells
Cardiovasc Res, January 1, 2007; 73(1): 66 - 72.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
F. X. Ma, B. Zhou, Z. Chen, Q. Ren, S. H. Lu, T. Sawamura, and Z. C. Han
Oxidized low density lipoprotein impairs endothelial progenitor cells by regulation of endothelial nitric oxide synthase
J. Lipid Res., June 1, 2006; 47(6): 1227 - 1237.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J.-i. Hinagata, M. Kakutani, T. Fujii, T. Naruko, N. Inoue, Y. Fujita, J. L. Mehta, M. Ueda, and T. Sawamura
Oxidized LDL receptor LOX-1 is involved in neointimal hyperplasia after balloon arterial injury in a rat model
Cardiovasc Res, January 1, 2006; 69(1): 263 - 271.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. S. Goligorsky
Endothelial cell dysfunction: can't live with it, how to live without it
Am J Physiol Renal Physiol, May 1, 2005; 288(5): F871 - F880.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.